Lumos Labs

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Lumos Labs sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 7 completed top decile by trial count

Lumos Labs: 9 sponsored US clinical trials, none currently recruiting.

Lumos Labs sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. The most-studied condition in this pipeline is ADHD, with 2 trials.

Top-decile sponsor footprint

Lumos Labs ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

How the Lumos Labs archive is shaped

9 indexed studies, none listed as recruiting (0% open); 7 completed (78%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: ADHD (2 trials), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Lumos Labs: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Lumos Labs sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Lumos Labs4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Lumos Labs sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Lumos Labs sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Lumos Labs page

9 registered trials is a research-attention snapshot, not an endorsement of Lumos Labs or any single study.

  • None of Lumos Labs's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • ADHD is the condition Lumos Labs studies most, compare against other sponsors active in the same condition before evaluating a specific study. See ADHD trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Lumos Labs pipeline card: 9 registered trials from official public datasets.Report a data error.